Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prognostic factors in multiple myeloma

R A Kyle1

  • 1Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.

Stem Cells (Dayton, Ohio)
|August 1, 1995
PubMed
Summary

Prognostic factors like plasma cell labeling index (PCLI) and beta 2-microglobulin (beta 2-M) help predict multiple myeloma survival. Elevated levels indicate higher risk, while normal levels suggest better outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medical mythology: Apollo.

Mayo Clinic proceedings·1992
Same author

Amyloidosis. Introduction and overview.

Journal of internal medicine·1992
Same author

Primary systemic amyloidosis.

Journal of internal medicine·1992
Same author

Wladyslaw Bieganski--father of modern Polish medicine.

Mayo Clinic proceedings·1992
Same author

Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients.

Archives of internal medicine·1992
Same author

Medical mythology: Hera (Juno).

Mayo Clinic proceedings·1992

Area of Science:

  • Hematology
  • Oncology
  • Clinical Medicine

Background:

  • Multiple myeloma survival varies significantly among patients.
  • Established prognostic factors include renal function, hemoglobin, calcium, and performance status.
  • Identifying more precise prognostic markers is crucial for patient management.

Purpose of the Study:

  • To evaluate the prognostic significance of various biomarkers in newly diagnosed multiple myeloma.
  • To identify independent predictors of survival in multiple myeloma patients.

Main Methods:

  • Analysis of 107 newly diagnosed multiple myeloma patients at the Mayo Clinic.
  • Assessment of univariate and independent prognostic factors including plasma cell labeling index (PCLI), thymidine kinase, beta 2-microglobulin (beta 2-M), serum albumin, C-reactive protein, age, interleukin 6 (IL-6), lactate dehydrogenase, and soluble IL-6 receptor (sIL-6R).

Main Results:

  • Plasma cell labeling index (PCLI) and beta 2-microglobulin (beta 2-M) were significant independent prognostic factors.
  • Elevated lactate dehydrogenase and soluble IL-6 receptor (sIL-6R) levels were associated with poor prognosis and shorter survival.
  • Patients with elevated PCLI, beta 2-M, or sIL-6R had a 2-year survival of 41%, compared to 83% when none were elevated.

Conclusions:

  • PCLI and beta 2-M are key independent prognostic indicators in multiple myeloma.
  • Incorporating markers like sIL-6R can improve risk stratification, identifying high-risk patients more effectively.
  • These findings aid in predicting survival outcomes and guiding treatment strategies for multiple myeloma.

Related Experiment Videos